Colwell J A, Bingham S F, Abraira C, Anderson J W, Comstock J P, Kwaan H C, Nuttall F
VA Medical Center, Charleston, SC 29403.
J Diabet Complications. 1989 Oct-Dec;3(4):191-7. doi: 10.1016/0891-6632(89)90029-9.
We report on unobserved, sudden, and unexpected deaths that occurred in a randomized multicenter trial. The long-term effects of aspirin plus dipyridamole on major vascular outcome variables were studied in 231 non insulin-dependent diabetic men with either a recent amputation for gangrene or active gangrene. Depending upon the definition of sudden death used, there were 14, 22, or 17 deaths in the drug group versus 6, 6, or 3 deaths in the placebo group (p = 0.04, 0.001, or 0.001, respectively). Total deaths from atherosclerotic vascular disease or deaths from all causes did not differ in the two treatment groups. Since this finding of a secondary end point is found only after multiple analyses of the data, it must be interpreted with caution. However, it is suggested that further studies on effects of antiplatelet agents on sudden deaths should be performed.
我们报告了一项随机多中心试验中发生的未被观察到的、突然的和意外的死亡情况。在231名近期因坏疽进行截肢或患有活动性坏疽的非胰岛素依赖型糖尿病男性中,研究了阿司匹林加双嘧达莫对主要血管结局变量的长期影响。根据所采用的猝死定义,药物组分别有14例、22例或17例死亡,而安慰剂组分别有6例、6例或3例死亡(p值分别为0.04、0.001或0.001)。两个治疗组中动脉粥样硬化性血管疾病导致的总死亡数或所有原因导致的死亡数并无差异。由于这一关于次要终点的发现是在对数据进行多次分析后才得出的,因此必须谨慎解读。然而,建议对抗血小板药物对猝死的影响进行进一步研究。